EMA Recommends Extension of Indications for Dostarlimab By Ogkologos - January 23, 2025 523 0 Facebook Twitter Google+ Pinterest WhatsApp Change concerns the first-line treatment of patients with endometrial cancer Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Brentuximab Approved for High-Risk Hodgkin Lymphoma in Children and Adolescents December 15, 2022 2023 Highlights in Treating Genitourinary Cancers: Expert Perspectives January 24, 2024 Five-Year Follow-up of Adjuvant Dabrafenib plus Trametinib in Resected Stage III... September 11, 2020 Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk... September 9, 2025 Load more HOT NEWS How cancer hijacks cell death: a new view of metastasis The Nobel Prize in Chemistry 2020 was Awarded “for the Development... Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why Stringently Defined Clinical Complete Response After Gemcitabine, Cisplatin, Plus Nivolumab Facilitates...
